A computer generated image of the Ebola virus
… Great Progress In The Fight Against The Deadly Ebola Virus …


Another vaccine breakthrough by Merck

Elements of innovation to combat the Ebola virus:

  • FDA and CHMP approves Merck’s Ebola vaccine “Ervebo”
  • The FDA had Ervebo’s review slated for review in the first quarter of 2020 and then re-prioritized it so it’s approval was completed in mid- December 2019
  • The Merck Ebola vaccine is administered via a single injection
  • Ervebo is genetically engineered to express a glycoprotein from the Zaire Ebola virus so as to provoke a neutralizing immune response
  • Johnson & Johnson has an Ebola vaccine currently deployed in Africa as a government authorized emergency measure prior to its approval by regulators

Merck ( NYSE: MRK ) has announced its Ebola vaccine, Ervebo, has been approved by European regulators ( followed with approval by the FDA )

Ervebo’s journey from development to approval

Ervebo is genetically engineered

An ongoing threat of Ebola outbreak surpasses a year

Why and how Ebola is such an enormous health threat

Due to its deadly attributes ( Ebola mortality rate is 50% to 90% ) as well as contagious makeup, Ebola is a major challenge for not only the individuals it infects initially but also a ruthless danger for caregivers and medical professionals of Ebola patients who must also take thorough precautions to protect themselves

Government and healthcare leaders limited to a single strategy for Ebola outbreaks until a vaccine was developed

Ebola’s primary origins, host carriers and transmission conduits continue to warrant research

This drives researchers to continue to search for more than one host beyond the fruit bat as an Ebola host. Given the rich biological environment of the Congo region, amazing diversity of wildlife in Africa as well as migrating populations of various species, this compounds the challenges involved with host identification

Ebola’s Deadly History

Merck is a global leader in vaccine immunization development

A second Ebola vaccine producer needs to enter the market